Mounjaro vs Ozempic:
Side-by-Side Comparison for Weight Loss

This is the most important distinction between the two medications, and most comparisons bury it. They target different receptors.

Ozempic (semaglutide) is a GLP-1 receptor agonist. It mimics the GLP-1 hormone your gut produces after eating. This slows gastric emptying, signals satiety to your brain, reduces glucagon secretion, and improves insulin sensitivity. One hormone, one receptor.

Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist. It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is another incretin hormone involved in fat metabolism and insulin secretion. The dual mechanism appears to produce stronger effects on appetite, insulin sensitivity, and fat loss.

Head-to-head comparisons matter more than marketing. Here's what the landmark trials found.

STEP 1 (Semaglutide 2.4 mg — Wegovy dose)

• 1,961 participants, 68 weeks
• Average weight loss: 14.9% of body weight (vs 2.4% placebo)
• About one-third of participants lost 20% or more of their body weight

SURMOUNT-1 (Tirzepatide — Mounjaro)

• 2,539 participants, 72 weeks
• Average weight loss at the highest dose (15 mg): 22.5% of body weight (vs 2.4% placebo)
• At 10 mg: 19.5%
• At 5 mg: 15.0%
• Over half of participants on the highest dose lost 20% or more

The numbers are clear: tirzepatide at its highest dose produces roughly 50% more weight loss than semaglutide at its highest dose. Even the lowest tirzepatide dose (5 mg) matched semaglutide's best result.

The SURMOUNT-2 trial in people with type 2 diabetes showed similar advantages. At 15 mg, tirzepatide produced 14.7% weight loss compared to semaglutide's typical 9–10% in the SUSTAIN trials for the diabetic population.

Both medications share GLP-1 activity, so their side effect profiles overlap significantly. GI symptoms dominate both.

Nausea

• Semaglutide (STEP 1): 44% of participants
• Tirzepatide (SURMOUNT-1): 24–33% depending on dose

Diarrhea

• Semaglutide: 32%
• Tirzepatide: 19–25%

Constipation

• Semaglutide: 24%
• Tirzepatide: 14–20%

Vomiting

• Semaglutide: 25%
• Tirzepatide: 6–12%

Discontinuation rates due to adverse events were similar — about 4–7% for both medications. Most GI symptoms are front-loaded in months 1–3 and resolve or become manageable.

Both carry warnings for thyroid C-cell tumors (based on rodent studies), pancreatitis, and gallbladder issues. Both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.

As of early 2026, list prices before insurance are in the same ballpark — roughly $900–$1,100 per month for both medications. But the reality of what you pay depends entirely on your insurance.

• Ozempic has been on the market longer (approved 2017 for diabetes) and generally has broader insurance coverage for type 2 diabetes. Wegovy (the weight-loss branded version of semaglutide at 2.4 mg) has more limited coverage for weight management.
• Mounjaro (approved 2022 for diabetes) gained its weight-loss indication under the brand name Zepbound in late 2023. Coverage is expanding but still lags behind Ozempic in many formularies.

Both manufacturers offer savings cards that can reduce copays to $25–$50/month for commercially insured patients. Without insurance, GoodRx and manufacturer programs sometimes bring costs down to $500–$600/month — still expensive.

Compounded semaglutide has been widely available due to ongoing shortages, often at $200–$400 per month. Compounded tirzepatide availability varies. Always verify that compounded versions come from a 503B outsourcing facility or a licensed 503A pharmacy with a valid prescription.

Both medications use slow dose escalation to minimize side effects.

Semaglutide (Ozempic): 0.25 mg for 4 weeks, then 0.5 mg for 4 weeks, then 1.0 mg, with an option to increase to 2.0 mg. The Wegovy formulation goes up to 2.4 mg. Total ramp-up: roughly 4–5 months to reach full dose.

Tirzepatide (Mounjaro): 2.5 mg for 4 weeks, then 5 mg for 4 weeks, then 7.5 mg, 10 mg, 12.5 mg, up to 15 mg. Each step is 4 weeks. Total ramp-up: roughly 5–6 months to reach maximum dose.

Both are weekly injections. Both use autoinjector pens. The injection experience is nearly identical from a patient perspective.

There is no universal "better." The right choice depends on your situation.

Mounjaro/Zepbound may be better if:

• You have a large amount of weight to lose (the higher ceiling of 22.5% average loss matters more)
• You're sensitive to nausea and want to minimize GI side effects
• You have type 2 diabetes — tirzepatide showed superior A1C reduction vs semaglutide in the SURPASS-2 trial
• Your insurance covers it or cost is not a barrier

Ozempic/Wegovy may be better if:

• Your insurance covers semaglutide but not tirzepatide (still common in 2026)
• You have cardiovascular risk — semaglutide has the SELECT trial showing a 20% reduction in major cardiovascular events, a benefit not yet demonstrated for tirzepatide
• You want a medication with a longer track record and more post-market safety data
• Compounded access is important to you — semaglutide compounds are more widely available

Both medications cause significant lean mass loss alongside fat loss. In STEP 1, approximately 40% of weight lost was lean mass. SURMOUNT-1 reported similar ratios.

This is not specific to either medication — it's a consequence of rapid caloric deficit. The mitigation strategy is the same for both:

• Resistance training 2–4 times per week
• Protein intake of 0.7–1.0g per pound of body weight daily
• Avoiding caloric intake below 1,200 calories/day

See our guide to preventing muscle loss on GLP-1 medications for a detailed protocol.

Tirzepatide (Mounjaro) produces more weight loss with fewer GI side effects based on clinical trial data. Semaglutide (Ozempic) has a longer track record, broader insurance coverage, and proven cardiovascular benefits. Both are effective. Both require the same lifestyle foundations — protein, resistance training, hydration, and consistent tracking.

Whichever you're on, what matters most after the first few months is not which medication you chose — it's whether you're protecting muscle, eating enough protein, and tracking the patterns that help your prescriber optimize your dose.